Efficacy of Quetiapine in Parkinson's Psychosis
| ISRCTN | ISRCTN74681449 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN74681449 |
| Secondary identifying numbers | KCL/KCH-CT2004-1 |
- Submission date
- 14/07/2005
- Registration date
- 09/09/2005
- Last edited
- 06/10/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Anthony David
Scientific
Scientific
Institute of Psychiatry
P.O. Box 68
De Crespigny Park
Denmark Hill
London
SE5 8AF
United Kingdom
| Phone | +44 (0)207 848 0138 |
|---|---|
| A.David@iop.kcl.ac.uk |
Study information
| Study design | Randomised placebo controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Treatment |
| Scientific title | |
| Study acronym | EQuiPP |
| Study objectives | The study hypothesis is that Quetiapine is effective in the treatment of the psychotic symptoms (hallucinations/delusions) seen in Parkinson's disease |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Parkinson's disease |
| Intervention | Quetiapine versus Placebo |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Quetiapine |
| Primary outcome measure | 1. Improvment in psychotic symptoms 2. Parkinsonian symptoms 3. Depressive symptoms 4. Remaining in the trial for the 12 week duration (patients will be withdrawn if their psychotic symptoms worsen) |
| Secondary outcome measures | 1. Activities of daily living 2. Cognitive function 3. Carer burden |
| Overall study start date | 01/08/2005 |
| Completion date | 01/08/2006 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 60 |
| Key inclusion criteria | 1. Hallucinations, delusions of a severity >3/7 on the Brief Psychiatric Rating Scale, 2. Diagnosis of Parkinson's which meets UKPD Society Brain Bank criteria |
| Key exclusion criteria | 1. Anti-psychotic medication in the preceding 3 months 2. Any contra-indication to quetiapine 3. Any important drug interactions 4. Major concomitant medical illness 5. History of uncontrolled diabetes or hypertension 6. Changes in medication in the last 14 days |
| Date of first enrolment | 01/08/2005 |
| Date of final enrolment | 01/08/2006 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Institute of Psychiatry
London
SE5 8AF
United Kingdom
SE5 8AF
United Kingdom
Sponsor information
King's College London (UK)
University/education
University/education
c/o Gill Dale
P.O. Box 005
The Institute of Psychiatry
De Crespigny Park
Denmark Hill
London
SE5 8AF
England
United Kingdom
| Website | http://www.iop.kcl.ac.uk |
|---|---|
"ROR" |
https://ror.org/0220mzb33 |
Funders
Funder type
Charity
Parkinson's Disease Society (UK) (Ref: 4052)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/10/2009 | Yes | No |
